AU2017248394B2 - Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia - Google Patents

Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia Download PDF

Info

Publication number
AU2017248394B2
AU2017248394B2 AU2017248394A AU2017248394A AU2017248394B2 AU 2017248394 B2 AU2017248394 B2 AU 2017248394B2 AU 2017248394 A AU2017248394 A AU 2017248394A AU 2017248394 A AU2017248394 A AU 2017248394A AU 2017248394 B2 AU2017248394 B2 AU 2017248394B2
Authority
AU
Australia
Prior art keywords
molar ratio
certain embodiments
amb
cholesterol
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017248394A
Other languages
English (en)
Other versions
AU2017248394A1 (en
Inventor
Martin D. Burke
Katrina A. Muraglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Publication of AU2017248394A1 publication Critical patent/AU2017248394A1/en
Application granted granted Critical
Publication of AU2017248394B2 publication Critical patent/AU2017248394B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017248394A 2016-04-08 2017-04-10 Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia Active AU2017248394B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662320111P 2016-04-08 2016-04-08
US62/320,111 2016-04-08
US201662320795P 2016-04-11 2016-04-11
US62/320,795 2016-04-11
PCT/US2017/026806 WO2017177228A1 (en) 2016-04-08 2017-04-10 Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia

Publications (2)

Publication Number Publication Date
AU2017248394A1 AU2017248394A1 (en) 2018-11-22
AU2017248394B2 true AU2017248394B2 (en) 2023-02-23

Family

ID=60001496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017248394A Active AU2017248394B2 (en) 2016-04-08 2017-04-10 Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia

Country Status (9)

Country Link
US (2) US20190083517A1 (enExample)
EP (1) EP3439668B1 (enExample)
JP (1) JP7041961B2 (enExample)
AU (1) AU2017248394B2 (enExample)
DK (1) DK3439668T3 (enExample)
ES (1) ES2983639T3 (enExample)
FI (1) FI3439668T3 (enExample)
PT (1) PT3439668T (enExample)
WO (1) WO2017177228A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2983639T3 (es) 2016-04-08 2024-10-24 The Board Of Trustees Of The Univ Illinois Restauración mediada por moléculas pequeñas de la fisiología de la superficie de las vías respiratorias en epitelios pulmonares humanos de fibrosis quística
DK3694526T3 (da) * 2017-10-11 2025-02-03 Univ Illinois Genotype-agnostisk redning af cystisk fibrose med småmolekylære bicarbonatkanaler
CA3250825A1 (en) 2022-03-21 2023-09-28 Cystetic Medicines Inc PROSTHETIC COMPOSITIONS WITH ION CHANNELS COMPRISING AMPHOTEROTIN B LIPID-COATED CRYSTALS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880101A (en) * 1994-06-28 1999-03-09 Dr. Zerle Gmbh Clinical uses of polyene macrolides
WO2008127358A2 (en) * 2006-10-10 2008-10-23 Jina Pharmaceuticals, Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
US20090220599A1 (en) * 2003-12-10 2009-09-03 Industrial Technology Research Institute Antifungal formulation and manufacturing method thereof
US8883748B2 (en) * 2009-10-16 2014-11-11 Lifecare Innovations Pvt. Ltd. Formulation for treating fungal infection
WO2015054148A1 (en) * 2013-10-07 2015-04-16 The Board Of Trustees Of The University Of Illinois Amphotericin b derivatives with improved therapeutic index

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
US20180015115A1 (en) * 2014-11-04 2018-01-18 The Board Of Trustees Of The University Of Illinois Restoring physiology with small molecule mimics of missing proteins
ES2983639T3 (es) 2016-04-08 2024-10-24 The Board Of Trustees Of The Univ Illinois Restauración mediada por moléculas pequeñas de la fisiología de la superficie de las vías respiratorias en epitelios pulmonares humanos de fibrosis quística

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880101A (en) * 1994-06-28 1999-03-09 Dr. Zerle Gmbh Clinical uses of polyene macrolides
US20090220599A1 (en) * 2003-12-10 2009-09-03 Industrial Technology Research Institute Antifungal formulation and manufacturing method thereof
WO2008127358A2 (en) * 2006-10-10 2008-10-23 Jina Pharmaceuticals, Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
US8883748B2 (en) * 2009-10-16 2014-11-11 Lifecare Innovations Pvt. Ltd. Formulation for treating fungal infection
WO2015054148A1 (en) * 2013-10-07 2015-04-16 The Board Of Trustees Of The University Of Illinois Amphotericin b derivatives with improved therapeutic index

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALEXANDER G CIOFFI ET AL: "Supporting Information for: Restored physiology in protein-deficient yeast by a small molecule channel", 1 January 2015 (2015-01-01), XP055639861, Retrieved from the Internet [retrieved on 20191107] *
ALEXANDER G. CIOFFI ET AL: "Restored Physiology in Protein-Deficient Yeast by a Small Molecule Channel", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 137, no. 32, 7 August 2015, US, pages 10096 - 10099. *
Chuealee R. Amphotericin B Incorporated in Liquid Crystals for Lung Fungal Infection Treatment. A Thesis, Doctor of Philosophy in Pharmaceutical Sciences, Prince of Songkla University, 2009 (249 pages) (Year: 2009) *
K. C. GRAY ET AL: "Amphotericin primarily kills yeast by simply binding ergosterol", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, VOL. 109, N.7, 17 January 2012 (2012-01-17), pages 2234 - 2239. *
THOMAS M ANDERSON ET AL: "Amphotericin forms an extramembranous and fungicidal sterol sponge", NATURE CHEMICAL BIOLOGY, VOL. 10, N.2, 1 May 2014 (2014-05-01), pages 400 - 406. *

Also Published As

Publication number Publication date
AU2017248394A1 (en) 2018-11-22
US20190083517A1 (en) 2019-03-21
US11850256B2 (en) 2023-12-26
EP3439668B1 (en) 2024-06-19
JP7041961B2 (ja) 2022-03-25
FI3439668T3 (fi) 2024-09-05
ES2983639T3 (es) 2024-10-24
WO2017177228A1 (en) 2017-10-12
EP3439668A4 (en) 2019-12-18
PT3439668T (pt) 2024-08-12
DK3439668T3 (da) 2024-09-02
US20210393661A1 (en) 2021-12-23
EP3439668A1 (en) 2019-02-13
JP2019510788A (ja) 2019-04-18

Similar Documents

Publication Publication Date Title
US11850256B2 (en) Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia
US20240043485A1 (en) Therapeutic use of bone morphogenetic proteins
US20240277743A1 (en) Restoring physiology with small molecule mimics of missing proteins
JP7774260B2 (ja) 細胞外ヒストンによって媒介される病理を処置及び予防するための化合物
US20250009775A1 (en) Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels
JP2015121550A (ja) 腎不全におけるゲルソリンの診断的および治療的使用
US9511087B2 (en) Use of antithrombin in extracorporeal membrane oxygenation
WO2025019806A2 (en) Restoring physiology with small molecule mimics of missing proteins
WO2024263742A1 (en) Combination therapy for the treatment of friedreich's ataxia
EP3612174A1 (en) Methods and pharmaceutical compositions for the treatment of diseases associated with reduced cftr function
US7557144B1 (en) Modulation of protein expression using carbocyclic aryl alkenoic acid derivatives
WO2000053174A1 (en) Modulation of protein expression using carbocyclic aryl alkenoic acid derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)